Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

End of Stabilisation Notice

20 Mar 2017 07:01

RNS Number : 8802Z
Arix Bioscience Plc
20 March 2017
 

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTIONS WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

20th March 2017

End of Stabilisation Notice

Arix Bioscience Plc (the "Company")

Pursuant to Article 6(3) of Commission Regulation (EC) 2016/1052 supplementing Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation, Jefferies International Limited (contact: Luca Erpici +44 (0)20 7029 8415; Lee Morton +44 (0)20 7029 8753) hereby gives notice that stabilisation was undertaken by the Stabilising Manager named below in relation to the offer of the following securities.

Issuer:

Arix Bioscience Plc

Securities:

Ordinary Shares (ISIN: GB00BD045071)

Description of Offer:

Initial Public Offering

Offer Price:

207p per ordinary share

Market:

London Stock Exchange, BATS, Chi-X, Turquoise

Ticker:

ARIX

Stabilising Manager:

Jefferies International Limited

Stabilisation Period:

17th February 2017 - 17th March 2017

 

Date

Lowest Price (pence)

Highest Price (pence)

 

Execution Venue

 

20/02/2017

205

207

London Stock Exchange

21/02/2017

206

207

London Stock Exchange

22/02/2017

207

207

London Stock Exchange

24/02/2017

207

207

London Stock Exchange

02/03/2017

207

207

London Stock Exchange

03/03/2017

207

207

London Stock Exchange

07/03/2017

206

207

London Stock Exchange, BATS, Chi-X, Turquoise

08/03/2017

207

207

London Stock Exchange

09/03/2017

207

207

London Stock Exchange

13/03/2017

207

207

London Stock Exchange

16/03/2017

206

207

London Stock Exchange, BATS, Chi-X, Turquoise

17/03/2017

207

207

London Stock Exchange

 

Disclaimer:

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy, fairness or completeness.

This announcement and copies of this announcement are not being made and may not be distributed, published, or sent, directly or indirectly, in whole or in part, in or into the United States, Australia, Canada, South Africa or Japan or to any persons in any of those jurisdictions or any other jurisdictions where to do so would be unlawful or would require registration or other measures. The release, publication or distribution of this announcement in other jurisdictions may be restricted by law and persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions.

The Offer and the distribution of this announcement and other information in connection with the listing and Offer in certain jurisdictions may be restricted by law and persons into whose possession this announcement, any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This announcement is not and does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase any securities in the United States, Australia, Canada, Japan, South Africa or any other jurisdiction where such an offer would be unlawful.

The Securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "US Securities Act") or with any securities regulatory authority of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States absent registration or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in compliance with any applicable laws of any state or other jurisdiction of the United States. The securities are being offered and sold outside the United States in offshore transactions as defined in, and in compliance with, Regulation S under the US Securities Act or within the United States only to "Qualified Institutional Buyers" ("QIBS") as defined in Rule 144A under the US Securities Act ("Rule 144"), who are also, in each case, "Qualified Purchasers" ("QPs"), as defined in section 2(a)(51) of the Investment Act of 1940, as amended (the "Investment Company Act"), or pursuant to another exemption form, or in a transaction not subject to, the registration requirements of the US Securities Act. Any forwarding, distribution or reproduction of this announcement, the publication in which it is contained and any copy of it in whole or in part is unauthorised. Failure to comply with this notice may result in a violation of the US Securities Act or the applicable laws or other jurisdictions. This announcement does not contain or constitute an offer to buy or subscribe for, the securities referred to herein to any person in any jurisdiction where it is unlawful to do so. The Company does not intend to register any part of the Offer in the United States and there will be no public offering of securities in the United States.

The Securities have not been and will not be registered under the applicable securities laws of Canada, Japan, South Africa or Australia and may not be offered or sold in Canada, Japan, South Africa or Australia except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the applicable securities laws. There will be no public offering of securities in Canada, Japan, South Africa or Australia.

This announcement is only addressed to, and directed at, persons in member states of the European Economic Area who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive ("Qualified Investors"). For the purposes of this provision, the expression "Prospectus Directive" means Directive 2003/71/EC (as amended) and includes any relevant implementing measure in each member state of the European Economic Area which has implemented the Prospectus Directive. In addition, in the United Kingdom, this announcement is being distributed only to, and is directed only at, Qualified Investors (i) who have professional experience in matters relating to investments who fall within the definition of "investment professional" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) who are high net worth companies, unincorporated associations and partnerships and trustees of high value trusts or other persons to whom it may otherwise lawfully be communicated falling within Article 49(2)(a)-(d) of the Order, (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this announcement relates is available only to and will only be engaged in with such persons. This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons; and (ii) in any member state of the European Economic Area other than the United Kingdom, by persons who are not Qualified Investors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STADXGDXISBBGRC
Date   Source Headline
7th Feb 202411:30 amEQSTransaction Update
29th Jan 202412:15 pmEQSResults of First General Meeting
24th Jan 20245:30 pmEQSHolding(s) in Company
24th Jan 20245:30 pmEQSHolding(s) in Company
23rd Jan 20247:00 amEQSUpdate on the Scheme and Publication of Notice of Second General Meeting
22nd Jan 20247:00 amEQSUpdate on the Scheme and Resignation of Directors
19th Jan 20247:01 amEQSFinancial update on Harpoon Therapeutics acquisition by Merck (MSD)
19th Jan 20247:00 amEQSUnaudited NAV for December 2023
8th Jan 20245:15 pmEQSPortfolio company Harpoon Therapeutics to be acquired by Merck (MSD)
5th Jan 20247:00 amEQSPublication of Circular and RTW Bio Prospectus
4th Jan 20245:30 pmEQSHolding(s) in Company
22nd Dec 202311:00 amEQSUpdate regarding timing of Proposed Scheme of Reconstruction
13th Dec 20237:00 amEQSUnaudited NAV for November 2023
8th Dec 20237:00 amEQSPortfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
13th Nov 20234:00 pmEQSCorrection: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
10th Nov 20238:00 amEQSPortfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
10th Nov 20237:00 amEQSPDMR Notification & Director Shareholding
8th Nov 20237:05 amEQSUnaudited NAV for October 2023
3rd Nov 20234:30 pmEQSPDMR Notification & Director Shareholding
2nd Nov 20236:20 pmEQSPDMR Notification & Director Shareholding
1st Nov 20234:30 pmEQSPortfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
1st Nov 20237:06 amRNSRTW Biotech to acquire Arix Bioscience's assets
24th Oct 20237:00 amEQSPortfolio company Harpoon Therapeutics announces up to $150 million private placement
6th Oct 20237:00 amEQSUnaudited NAV for September 2023
27th Sep 20237:01 amEQSInterim Results for the Six Months Ended 30 June 2023
27th Sep 20237:00 amEQSBoard Change
14th Sep 20237:01 amEQSNotice of Results and Investor Presentation
14th Sep 20237:00 amEQSUnaudited NAV for August 2023
7th Aug 20237:00 amEQSUnaudited NAV for July 2023
17th Jul 20233:00 pmEQSHolding(s) in Company
13th Jul 20237:01 amEQSArix Announces Strategic Review
13th Jul 20237:00 amEQSUnaudited NAV for June 2023
23rd Jun 20232:04 pmEQSPortfolio company Disc Medicine raises $157.8 million in public offering
9th Jun 20232:53 pmEQSPortfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA
9th Jun 20237:00 amEQSUnaudited NAV for May 2023
31st May 202311:51 amRNSDirector/PDMR Shareholding
24th May 20237:00 amEQSCorrection: Result of Annual General Meeting
23rd May 20234:30 pmEQSResult of Annual General Meeting
16th May 20234:36 pmEQSPortfolio company Ensoma announces closing of Series B Extension
12th May 20237:00 amEQSUnaudited NAV for April 2023
5th May 20234:30 pmRNSTotal Voting Rights
4th May 20235:02 pmRNSDirector/PDMR Shareholding
4th May 202312:15 pmRNSDirector/PDMR Shareholding
2nd May 20233:52 pmRNSDirector/PDMR Shareholding
27th Apr 20237:00 amEQSArix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune
25th Apr 20237:03 amEQSFinancial Results for the Year Ended 31 December 2022, Publication of Annual Report & Notice of AGM
19th Apr 20231:30 pmEQSFull Year results now to be released on 25 April 2023
17th Apr 20237:00 amEQSUnaudited NAV for March 2023
14th Apr 202312:00 pmEQSNotice of Results and Investor Presentation
28th Mar 20237:00 amEQSPortfolio company Harpoon Therapeutics announces closing of $25 million private placement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.